{"id":"https://openalex.org/W2602331950","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps2631","title":"Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors.","display_name":"Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors.","publication_year":2014,"publication_date":"2014-05-20","ids":{"openalex":"https://openalex.org/W2602331950","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps2631","mag":"2602331950"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2014.32.15_suppl.tps2631","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps2631","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps2631","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112421072","display_name":"Chia\u2010Chi Lin","orcid":"https://orcid.org/0000-0002-2573-5789","observed_orcids":["https://orcid.org/0000-0002-2573-5789","https://orcid.org/0009-0006-5084-0819"]},"institutions":[{"id":"https://openalex.org/I4210131804","display_name":"National Taiwan University Hospital","ror":"https://ror.org/03nteze27","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210131804"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"Chia-Chi Lin","raw_affiliation_strings":["Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan","InnoPharmax Inc., Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan","institution_ids":["https://openalex.org/I4210131804"]},{"raw_affiliation_string":"InnoPharmax Inc., Taipei, Taiwan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028823803","display_name":"Wu\u2010Chou Su","orcid":"https://orcid.org/0000-0003-2953-4105","observed_orcids":["https://orcid.org/0000-0003-2953-4105"]},"institutions":[{"id":"https://openalex.org/I4210158999","display_name":"National Cheng Kung University Hospital","ror":"https://ror.org/04zx3rq17","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210158999"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"Wu-Chou Su","raw_affiliation_strings":["National Cheng Kung University Hospital, Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cheng Kung University Hospital, Taipei, Taiwan","institution_ids":["https://openalex.org/I4210158999"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052678985","display_name":"Jih\u2010Hsiang Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210131804","display_name":"National Taiwan University Hospital","ror":"https://ror.org/03nteze27","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210131804"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"Jih-hsiang Lee","raw_affiliation_strings":["Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan","institution_ids":["https://openalex.org/I4210131804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090591171","display_name":"Chih\u2010Hung Hsu","orcid":"https://orcid.org/0000-0003-0495-973X","observed_orcids":["https://orcid.org/0000-0003-0495-973X"]},"institutions":[{"id":"https://openalex.org/I4210131804","display_name":"National Taiwan University Hospital","ror":"https://ror.org/03nteze27","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210131804"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"Chih-Hung Hsu","raw_affiliation_strings":["Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan","institution_ids":["https://openalex.org/I4210131804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017953971","display_name":"Ann\u2010Lii Cheng","orcid":"https://orcid.org/0000-0002-9152-6512","observed_orcids":["https://orcid.org/0000-0002-9152-6512"]},"institutions":[{"id":"https://openalex.org/I4210131804","display_name":"National Taiwan University Hospital","ror":"https://ror.org/03nteze27","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210131804"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"Ann-Lii Cheng","raw_affiliation_strings":["National Taiwan University Hospital, Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Taiwan University Hospital, Taipei, Taiwan","institution_ids":["https://openalex.org/I4210131804"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070690878","display_name":"Chia-Li Lin","orcid":"https://orcid.org/0000-0003-3757-1862","observed_orcids":["https://orcid.org/0000-0003-3757-1862"]},"institutions":[{"id":"https://openalex.org/I4210131804","display_name":"National Taiwan University Hospital","ror":"https://ror.org/03nteze27","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210131804"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"Chia-Li Lin","raw_affiliation_strings":["Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan","InnoPharmax Inc., Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan","institution_ids":["https://openalex.org/I4210131804"]},{"raw_affiliation_string":"InnoPharmax Inc., Taipei, Taiwan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102313635","display_name":"Hsiang\u2010Ling Ho","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hsiang-Ling Ho","raw_affiliation_strings":["InnoPharmax Inc., Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"InnoPharmax Inc., Taipei, Taiwan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066729032","display_name":"Chia-Tsung Huang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chia-Tsung Huang","raw_affiliation_strings":["InnoPharmax Inc., Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"InnoPharmax Inc., Taipei, Taiwan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074855245","display_name":"Shu-Ping Hsueh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shu-Ping Hsueh","raw_affiliation_strings":["InnoPharmax Inc., Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"InnoPharmax Inc., Taipei, Taiwan","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5055074037","display_name":"James Chih\u2010Hsin Yang","orcid":"https://orcid.org/0000-0002-5586-5138","observed_orcids":["https://orcid.org/0000-0002-5586-5138"]},"institutions":[{"id":"https://openalex.org/I4210131804","display_name":"National Taiwan University Hospital","ror":"https://ror.org/03nteze27","country_code":"TW","type":"healthcare","lineage":["https://openalex.org/I4210131804"]}],"countries":["TW"],"is_corresponding":false,"raw_author_name":"James Chih-Hsin Yang","raw_affiliation_strings":["Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan","institution_ids":["https://openalex.org/I4210131804"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"32","issue":"15_suppl","first_page":"TPS2631","last_page":"TPS2631"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.42239999771118164,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.42239999771118164,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.20399999618530273,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.049800001084804535,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.8479999899864197},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8610000014305115},{"id":"https://openalex.org/keywords/lymphoma","display_name":"lymphoma","score":0.9409999847412109},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6729999780654907},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.9760000109672546},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9950000047683716},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9409999847412109},{"id":"https://openalex.org/keywords/first-pass-metabolism","display_name":"first-pass metabolism","score":0.8550000190734863},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7839999794960022}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9019325971603394},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.8897638320922852},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8156640529632568},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.748376727104187},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.653876006603241},{"id":"https://openalex.org/C2777333352","wikidata":"https://www.wikidata.org/wiki/Q2689559","display_name":"Nucleoside analogue","level":3,"score":0.5867887735366821},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5220375061035156},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4461548924446106},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.42897307872772217},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4270760715007782},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.42591720819473267},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3970220983028412},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3708155155181885},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.342650830745697},{"id":"https://openalex.org/C2776543447","wikidata":"https://www.wikidata.org/wiki/Q28734","display_name":"Nucleoside","level":2,"score":0.18474194407463074},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2014.32.15_suppl.tps2631","doi":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps2631","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2014.32.15_suppl.tps2631","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2600952040","https://openalex.org/W4244171502","https://openalex.org/W2156646828","https://openalex.org/W4409676240","https://openalex.org/W7113638276","https://openalex.org/W2084084559","https://openalex.org/W1966551323","https://openalex.org/W4379282515","https://openalex.org/W2150828354","https://openalex.org/W2336100460"],"abstract_inverted_index":{"TPS2631^":[0],"Background:":[1],"Gemcitabine":[2],"HCl":[3,25,88],"is":[4,13,81,90,106,206,216,249],"a":[5,36,61,82,202],"nucleoside":[6],"analogue":[7],"that":[8,89],"exhibits":[9],"antitumor":[10],"activity":[11,50],"and":[12,29,56,100,135,151,166,171,199,225],"approved":[14],"for":[15,231,251],"IV":[16],"use":[17],"in":[18,53,60,110,116,211,234,240],"the":[19,31,65,94,152],"world.":[20],"Oral":[21],"dosing":[22],"of":[23,51,86,109,145,157,163,168,176,201],"gemcitabine":[24,52,70,87],"would":[26],"simplify":[27],"administration":[28],"extend":[30],"systemic":[32,66,95],"exposure":[33,42,67,96],"time":[34],"after":[35],"dose":[37,113,156],"relative":[38],"to":[39,68,74,78,92,97,178,187,219,245],"an":[40,111],"intravenous":[41],"profile,":[43],"which":[44],"has":[45,238],"been":[46],"correlated":[47],"with":[48,118,126,136],"increased":[49],"both":[54],"pre-clinical":[55],"clinical":[57,63],"studies.":[58],"Nonetheless,":[59],"reported":[62],"study,":[64],"oral":[69,84,138,190],"was":[71],"low":[72],"due":[73],"extensive":[75],"first-pass":[76],"metabolism":[77],"dFdU.":[79],"D07001-F4":[80,105,191],"unique":[83],"formulation":[85],"expected":[91],"enhance":[93],"difluorodeoxycytidine":[98],"(dFdC)":[99],"ultimately":[101],"dFdCTP,":[102],"intracellularly.":[103],"Methods:":[104],"being":[107],"evaluated":[108],"open-label,":[112],"escalation":[114],"study":[115],"patients":[117,180],"advanced":[119],"solid":[120],"tumors":[121],"or":[122,221],"lymphoma.":[123],"Eligibility:":[124],"pts":[125],"evaluable":[127],"tumors,":[128],"age":[129],"\u00b3a":[130],"20":[131],"yrs,":[132],"PS":[133],"0\u20132":[134],"adequate":[137],"therapy":[139],"absorption.":[140],"Primary":[141],"objects":[142],"includes":[143],"determination":[144],"maximum":[146],"tolerated":[147],"dose,":[148],"dose-limiting":[149],"toxicity(ies)":[150],"recommended":[153],"phase":[154],"2":[155,185],"D07001-F4.":[158],"Secondary":[159],"objectives":[160],"include":[161],"characterization":[162],"pharmacokinetic":[164],"(PK)":[165],"assessment":[167],"safety,":[169],"tolerability":[170],"anti-tumor":[172],"activity.":[173],"Sequential":[174],"cohorts":[175],"3":[177],"6":[179],"receive":[181],"doses":[182],"ranging":[183],"from":[184],"mg":[186,189],"80":[188],"on":[192,209],"Days":[193],"1,":[194],"3,":[195],"5,":[196],"8,":[197],"10,":[198],"12":[200],"21-day":[203],"cycle.":[204],"MTD":[205],"determined":[207,217],"based":[208],"DLTs":[210],"cycle":[212,235],"1.":[213,236],"Tumor":[214],"response":[215],"according":[218],"RECIST":[220],"Cheson":[222],"criteria.":[223],"Plasma":[224],"peripheral":[226],"blood":[227],"samples":[228],"were":[229],"obtained":[230],"PK":[232],"analysis":[233],"Accrual":[237,248],"completed":[239],"Cohorts":[241],"1":[242],"(2":[243],"mg)":[244],"4":[246],"(20mg).":[247],"underway":[250],"Cohort":[252],"5":[253],"(30":[254],"mg).":[255],"Clinical":[256],"trial":[257],"information:":[258],"NCT01800630.":[259]},"counts_by_year":[],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2017-04-07T00:00:00"}